https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4
Skip to content 
Johnson & Johnson (NYSE: JNJ) reported its first quarter 2025 earnings results today. Reported sales increased 2.4% year-over-year to $21.9 billion. Operational sales growth was 4.2%. Net earnings rose to $11 billion, or $4.54 per share, from $3.25 billion, or $1.34 per share, last year. Adjusted EPS grew 2.2% to $2.77. For the full year … Read more
For Johnson & Johnson (NYSE: JNJ), investments in the pipeline and exiting lower priority businesses remain central to its strategy in the new fiscal year. The healthcare behemoth is in the midst of a major transformation, streamlining operations and further expanding its diversified portfolio. The company is preparing to report results for the first three … Read more
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2024 earnings results today. Reported sales increased 5.3% year-over-year to $22.5 billion. Operational sales growth was 6.7%. Net earnings decreased 17% to $3.4 billion, or $1.41 per share, compared to last year. Adjusted EPS decreased 10.9% to $2.04. Revenue surpassed projections while earnings came in line … Read more
Johnson & Johnson (NYSE: JNJ) is set to publish its December-quarter report on January 22, amid expectations for mixed results. The company, which has faced both challenges and tailwinds in recent years, is betting on its extensive drug pipeline and product launches to drive growth beyond 2025. Last year, the healthcare giant’s stock experienced high … Read more
https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4